What Is Peptide Therapy? Everything You Need to Know

Peptide therapy has gone from niche biohacking trend to mainstream medical treatment in just a few years. GLP-1 peptides like semaglutide made the category famous, but they’re just one slice of a much larger field — our complete list of peptides covers every major compound in use today.

At its core, peptide therapy uses short chains of amino acids — peptides — to trigger specific biological responses. Some are FDA-approved drugs with decades of clinical data. Others are compounded formulations operating in a regulatory gray zone. Knowing the difference matters, because what you’re actually getting varies enormously depending on which peptide, which source, and which clinic you choose.

Key Takeaways

• Peptides are short amino acid chains (2-50 amino acids) that act as signaling molecules, telling your body to do specific things — burn fat, heal tissue, release growth hormone, or modulate immunity [1]
• Several peptide therapies are fully FDA-approved, including semaglutide (weight loss), tesamorelin (HIV-related lipodystrophy), and bremelanotide/PT-141 (sexual dysfunction) [2]
• Many popular peptides like BPC-157 and CJC-1295 are NOT FDA-approved and were recently classified by the FDA as substances with safety concerns, restricting compounding [3]
• Costs range from $150-2,000/month depending on the peptide, dosing, and whether you’re using brand-name or compounded versions

Table of Contents

1. What Are Peptides?
2. How Peptide Therapy Works
3. Types of Peptide Therapy
4. FDA-Approved vs. Compounded Peptides
5. What Conditions Does Peptide Therapy Treat?
6. Administration Methods
7. The Regulatory Landscape in 2026
8. Finding a Qualified Provider
9. Cost Breakdown
10. Side Effects and Risks
11. FAQ
12. Sources

What Are Peptides?

Peptides are chains of amino acids — the same building blocks that make up proteins. The difference is size. Proteins are typically longer than 50 amino acids; peptides are shorter. Your body produces hundreds of peptides naturally, and they serve as chemical messengers that tell cells and organs what to do.

Insulin, for example, is a peptide your pancreas makes to regulate blood sugar. Oxytocin is a peptide that influences bonding and social behavior. GLP-1 is a gut peptide that controls appetite and blood sugar.

Peptide therapy uses synthetic versions of these molecules — or novel peptides designed to mimic their effects — to produce targeted biological responses. Think of them as precision tools. Unlike broad-acting drugs that affect multiple systems, peptides tend to have focused mechanisms of action because they interact with specific receptors [1].

How Peptide Therapy Works

Peptides work by binding to receptors on cell surfaces, just like a key fitting a lock. When the peptide binds, it triggers a cascade of intracellular signals that produce a specific effect.

Receptor Specificity

Each peptide targets particular receptors. GLP-1 peptides bind GLP-1 receptors in the gut, pancreas, and brain. Growth hormone-releasing peptides bind ghrelin receptors in the pituitary gland. This receptor specificity is why peptide side effects tend to be more predictable than those of small-molecule drugs that can interact with many different targets.

Signaling Cascades

Once a peptide binds its receptor, it doesn’t directly “do” anything to the cell. Instead, it initiates a signaling cascade — a chain of molecular events that amplifies the original signal. One peptide molecule binding one receptor can activate thousands of downstream molecules. That’s why small doses can produce significant effects.

Bioavailability Challenges

The catch with peptides: your digestive system breaks them down. That’s why most peptide therapies are injected subcutaneously (under the skin) rather than taken as pills. If you’re new to injections, our guide on how to reconstitute peptides covers preparation and dosing math. Some newer formulations use oral delivery with absorption enhancers, but injectable administration remains the standard for most peptides [4].

Types of Peptide Therapy

Peptide therapies generally fall into several functional categories based on what they target.

Weight Management Peptides

This is the category that put peptide therapy on the map. GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) have produced weight loss of 15-22% in clinical trials [5][6]. They work by suppressing appetite, slowing gastric emptying, and improving insulin sensitivity. These are FDA-approved, well-studied, and represent the gold standard of evidence-based peptide therapy.

Growth Hormone Secretagogues

These peptides stimulate your pituitary gland to release more growth hormone (GH). They don’t add external GH — they coax your body into making more of its own. Common examples include:

• Sermorelin: A 29-amino acid peptide that mimics growth hormone-releasing hormone (GHRH). FDA-approved for GH deficiency diagnosis, it’s also used off-label for anti-aging. Studies show it increases GH secretion while maintaining the body’s natural pulsatile release pattern [7].
• Tesamorelin (Egrifta): FDA-approved specifically for reducing visceral fat in HIV patients with lipodystrophy. It’s a GHRH analog that has shown meaningful reductions in trunk fat in clinical trials [8].
• CJC-1295 and Ipamorelin: Often prescribed together, these stimulate GH release through complementary mechanisms. CJC-1295 is a GHRH analog; ipamorelin is a ghrelin mimetic. However, as of 2025, the FDA has classified both as Category 2 substances with safety concerns, restricting their compounding [3].

Tissue Repair and Recovery Peptides

This is where the science gets thinner but the patient interest runs high.

• BPC-157 (Body Protection Compound-157): A 15-amino acid peptide derived from a protein found in gastric juice. Animal studies — and there are many — show remarkable effects on tendon, ligament, muscle, and gut healing [9]. It’s commonly paired with TB-500 in the wolverine peptide stack. The catch: there are no published human clinical trials. All the evidence is preclinical (rats, mostly). The FDA classified BPC-157 as a Category 2 substance in 2024, meaning compounding pharmacies cannot legally produce it [3].
• TB-500 (Thymosin Beta-4 fragment): Another tissue repair peptide with strong animal data and no human trials. Same regulatory restriction as BPC-157.

Immune-Modulating Peptides

• Thymosin Alpha-1 (Zadaxin): The most established peptide in this category. It’s approved in over 30 countries (though not the U.S.) for hepatitis B and C treatment. It stimulates T-cell production and has been studied in cancer immunotherapy as an adjunct [10]. The FDA placed it on the Category 2 list in the U.S., restricting compounding.

Sexual Health Peptides

• Bremelanotide (Vyleesi/PT-141): FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works through melanocortin receptors in the brain rather than through vascular mechanisms like sildenafil [2]. Administered as a subcutaneous injection before anticipated sexual activity.

Skin and Hair Peptides

• GHK-Cu (Copper peptide): A naturally occurring tripeptide that declines with age. Topical formulations are used in skincare for wound healing and collagen stimulation. Injectable forms have been restricted by the FDA [3]. Topical application has some clinical support for skin rejuvenation [11].

FDA-Approved vs. Compounded Peptides

This distinction matters more than almost anything else in peptide therapy. The difference in evidence, quality control, and legal standing is enormous.

FDA-Approved Peptide Drugs

These have gone through full clinical trials demonstrating safety and efficacy. They’re manufactured under strict Good Manufacturing Practice (GMP) standards. Examples include:

• Semaglutide (Wegovy/Ozempic) — weight loss, diabetes, cardiovascular risk reduction
• Tirzepatide (Zepbound/Mounjaro) — weight loss, diabetes
• Liraglutide (Saxenda/Victoza) — weight loss, diabetes
• Tesamorelin (Egrifta) — HIV-related lipodystrophy
• Bremelanotide (Vyleesi) — HSDD in women
• Sermorelin — GH deficiency diagnosis (approved use is narrow)

With FDA-approved peptides, you know exactly what you’re getting: verified purity, consistent dosing, and a well-characterized safety profile from trials involving thousands of patients.

Compounded Peptides

Compounding pharmacies create custom formulations that aren’t commercially available. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, pharmacies can compound medications — but only using bulk drug substances that meet specific criteria.

Here’s where it gets complicated. In 2023-2024, the FDA began categorizing bulk peptide substances:

• Category 1: Can be compounded (e.g., sermorelin is generally permitted)
• Category 2: “Substances with safety concerns” — cannot be compounded. This list now includes BPC-157, CJC-1295, ipamorelin, TB-500, thymosin alpha-1, GHK-Cu (injectable), and several others [3]
• Category 3: Under evaluation

The practical effect: many of the most popular “wellness peptides” are now legally off-limits from legitimate compounding pharmacies. Clinics still offering them are either operating under legal challenge, using gray-market sources, or haven’t updated their practices.

The Quality Gap

When compounded peptides were legally available, quality varied dramatically between pharmacies. Studies have found compounded peptides with as little as 60% of labeled potency, contamination with endotoxins, or incorrect amino acid sequences [12]. This isn’t universal — some 503B outsourcing facilities maintain excellent quality — but it’s a real risk when you’re not buying FDA-approved products.

What Conditions Does Peptide Therapy Treat?

Let’s separate what has strong evidence from what’s more speculative.

Strong Evidence (FDA-Approved Indications)

• Obesity and overweight: Semaglutide, tirzepatide, liraglutide — backed by trials with thousands of patients
• Type 2 diabetes: Same GLP-1 peptides, different brand names and dosing
• Cardiovascular risk reduction: Semaglutide (SELECT trial showed 20% reduction in major cardiovascular events) [13]
• HIV-related lipodystrophy: Tesamorelin
• Female sexual dysfunction: Bremelanotide

Moderate Evidence (Off-Label but Studied)

• Growth hormone deficiency in adults: Sermorelin (limited but real clinical data)
• Age-related GH decline: Growth hormone secretagogues (data is mixed; GH replacement itself is controversial for “anti-aging”)
• Muscle wasting: Some peptides show promise in preclinical models

Weak or Preclinical Evidence Only

• Tissue repair (tendons, ligaments, gut): BPC-157 and TB-500 have only animal studies. The effects in rats are striking, but we don’t know if they translate to humans [9].
• Immune enhancement: Thymosin alpha-1 has clinical data in other countries but limited U.S. trials for the wellness indications marketed by clinics.
• Cognitive enhancement: Peptides like Semax and Selank are approved in Russia but lack Western clinical trials.
• “Anti-aging”: The broadest and most poorly defined category. Some peptides may influence aging-related pathways, but no peptide has been proven to slow human aging.

Be skeptical of clinics claiming peptide therapy “treats” conditions based only on animal studies or mechanistic reasoning. The gap between “works in rats” and “works in humans” is wide and littered with failed drugs.

Administration Methods

Subcutaneous Injection

The most common route. A small needle (typically 29-31 gauge, half-inch) goes into the fat layer under the skin — usually the abdomen, thigh, or upper arm. Most patients learn to self-inject in a single training session. It’s less intimidating than it sounds.

Oral Administration

Historically, peptides couldn’t survive the digestive tract. That’s changing. Oral semaglutide (Rybelsus) uses an absorption enhancer called SNAC to get through the stomach lining. It works, but bioavailability is lower than the injectable form, so higher doses are needed [14].

Nasal Sprays

Some peptides (Semax, Selank) are administered nasally. Absorption through nasal mucosa avoids the GI tract. This route is less established for most therapeutic peptides.

Topical

GHK-Cu and some other peptides are applied to the skin in creams or serums. Penetration is limited to local effects, which is appropriate for skin-focused applications but won’t produce systemic effects.

Intravenous

Rarely used for peptide therapy outside hospital settings. Some clinics offer IV peptide infusions, but there’s little evidence this route offers advantages over subcutaneous injection for most peptides.

The Regulatory Landscape in 2026

The FDA’s approach to peptides has shifted dramatically in the last two years, and it’s still in flux.

The Category 2 Crackdown

Starting in late 2023, the FDA began placing popular compounded peptides on the Category 2 list (substances with safety concerns that cannot be compounded). As of early 2026, this list includes BPC-157, CJC-1295, ipamorelin, TB-500, thymosin alpha-1, AOD-9604, melanotan II, KPV, Selank, Semax, and others [3].

The FDA’s rationale: these substances haven’t gone through formal safety testing in humans. “Popular” doesn’t mean “proven safe.” The peptide therapy community has pushed back, arguing that decades of clinical use without major safety signals should count for something.

Legal Challenges

Several compounding pharmacies and industry groups have filed legal challenges against the FDA’s Category 2 designations. Some have won temporary injunctions allowing continued compounding. The legal situation varies by jurisdiction and is likely to remain unsettled through 2026 [3].

What This Means for Patients

If you’re interested in peptide therapy, the regulatory environment has two practical implications:

1. FDA-approved peptides are the safest legal choice. They have defined safety profiles, consistent manufacturing, and your provider can prescribe them with confidence.
2. Non-FDA-approved peptides carry both medical and legal uncertainty. Even if a clinic offers them, the source, quality, and legal status may be questionable. Ask your provider where their peptides come from and under what legal authority they’re being prescribed.

Finding a Qualified Provider

Not all peptide therapy providers are created equal. Here’s what to look for.

Credentials That Matter

• Board-certified physician (MD or DO) in endocrinology, internal medicine, obesity medicine, or sports medicine
• Anti-Aging/Regenerative medicine fellowship or certification (A4M, ABAARM) — adds relevant training, though not universally required
• Experience with the specific peptide you’re considering — ask how many patients they’ve treated and what outcomes they typically see

Red Flags

• Clinics that prescribe peptides without bloodwork or physical examination
• Providers who guarantee specific results (“lose 30 lbs in 60 days”)
• Businesses selling peptides directly without a prescriber relationship
• Clinics offering Category 2 peptides without acknowledging regulatory restrictions
• Any provider who dismisses side effects or monitoring as unnecessary

Questions to Ask

• Where do you source your peptides? (Look for FDA-approved manufacturers or accredited 503B outsourcing facilities)
• What monitoring will I need? (Blood work, follow-up visits)
• What’s the evidence base for this specific peptide for my condition?
• What’s the plan if I don’t respond or have side effects?

Cost Breakdown

Peptide therapy costs vary widely. Here’s a realistic range based on 2025-2026 pricing.

FDA-Approved Peptides

• Semaglutide (Wegovy): $499-1,349/month depending on source (NovoCare direct vs. pharmacy)
• Tirzepatide (Zepbound): Variable; Lilly offers direct cash-pay options. Pharmacy list prices run $1,000+/month
• Liraglutide (Saxenda): $1,000-1,300/month
• Tesamorelin (Egrifta): ~$1,000-2,000/month
• Bremelanotide (Vyleesi): ~$900 per 4-dose carton

Compounded Peptides (Where Legally Available)

• Sermorelin: $150-500/month
• Growth hormone secretagogue blends: $200-600/month
• BPC-157 (where still accessible): $150-400/month

Additional Costs

• Initial consultation: $100-300 (some clinics waive this)
• Blood work: $100-500 depending on panels ordered
• Follow-up visits: $50-200 per visit
• Supplies (syringes, alcohol swabs): $10-20/month

Insurance Coverage

Coverage for FDA-approved weight loss peptides has expanded but remains inconsistent. Many commercial plans cover Wegovy and Zepbound with prior authorization. Medicare began covering Wegovy for cardiovascular indications in 2025. Compounded peptides are almost never covered by insurance.

Side Effects and Risks

Side effects depend entirely on which peptide you’re using. There’s no single “peptide therapy side effect profile” because different peptides act through completely different mechanisms.

GLP-1 Peptides (Semaglutide, Tirzepatide, Liraglutide)

GI effects dominate: nausea (20-44%), diarrhea (15-30%), vomiting (6-24%), constipation (11-24%). Usually mild, usually temporary, worse during dose titration [5]. Rare but serious: pancreatitis, gallbladder disease. Boxed warning for thyroid C-cell tumors (rodent data only).

Growth Hormone Secretagogues

Water retention, joint pain, carpal tunnel-like symptoms, increased hunger (especially with ghrelin mimetics). Long-term risks of chronically elevated GH are not fully characterized for these newer peptides.

Tissue Repair Peptides (BPC-157, TB-500)

Here’s the honest answer: we don’t have reliable human safety data. Animal studies show minimal toxicity, but that’s a limited reassurance. Without human trials, the side effect profile is genuinely unknown [9].

General Injection-Site Reactions

Redness, swelling, or itching at the injection site is common across all injectable peptides. These are typically mild and resolve within hours.

FAQ

How long does peptide therapy take to work?▼

It depends on the peptide and the goal. GLP-1 weight loss peptides typically show noticeable effects within 4-8 weeks as doses are titrated up [5]. Growth hormone secretagogues may take 3-6 months for body composition changes. Tissue repair peptides (in anecdotal reports) often show effects within 2-4 weeks, but remember — there’s no controlled human data to benchmark against.

Is peptide therapy FDA-approved?▼

Some peptides are FDA-approved drugs with full clinical trial evidence — semaglutide, tirzepatide, liraglutide, tesamorelin, and bremelanotide, among others. Many popular “wellness” peptides (BPC-157, CJC-1295, ipamorelin) are not FDA-approved and have been restricted from compounding [3]. The term “peptide therapy” covers both categories, which is why specifics matter.

Are peptide injections painful?▼

Most patients describe subcutaneous peptide injections as a mild pinch or barely noticeable. The needles used (29-31 gauge) are extremely thin — similar to insulin needles. Injection-site soreness can occur but is usually minor. Most people get comfortable with self-injection within a week or two.

Can you do peptide therapy without a doctor?▼

You shouldn’t. FDA-approved peptides require a prescription. Beyond the legal issue, medical oversight matters for baseline blood work, contraindication screening, dose titration, and side effect monitoring. Online “research peptide” vendors sell unregulated products without prescriptions, but purity, potency, and safety are all unknown quantities [12].

What’s the difference between peptides and steroids?▼

Peptides are amino acid chains that signal your body’s own systems to act — they work through receptor activation and natural feedback loops. Anabolic steroids are synthetic hormones that directly override your body’s testosterone production. Peptides generally have more targeted effects, fewer systemic side effects, and don’t suppress natural hormone production the way steroids do. That said, growth hormone secretagogue peptides do share some overlap with HGH therapy in their goals, if not their mechanism.

Sources

1. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122-128. doi:10.1016/j.drudis.2014.10.003.

2. Kingsberg SA, Clayton AH, Pfaus JG, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500.

3. FDA Bulk Drug Substances That Can Be Used by Outsourcing Facilities, Category 2 List. Updated 2025. fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding.

4. Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. doi:10.1038/s41573-020-00135-8.

5. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID: 33567185.

6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID: 35658024.

7. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. doi:10.2165/00063030-199912020-00007.

8. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375.

9. Sikiric P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert’s cytoprotection, Selye’s stress coping response, and Hitomi’s preconditioning. Curr Pharm Des. 2020;26(25):2985-3000. doi:10.2174/1381612826666200320165737.

10. Tuthill C, Rios I, McBeath R. Thymalfasin: biological properties and clinical applications. Int Immunopharmacol. 2020;85:106580. doi:10.1016/j.intimp.2020.106580.

11. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108.

12. FDA Warning Letters to Compounding Pharmacies regarding peptide quality and potency violations, 2023-2025.

13. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563.

14. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. doi:10.1126/scitranslmed.aar7047.